Gregory Renza

Truist Securities | Healthcare

Gregory Renza is an analyst from Truist Securities specializing in the Healthcare sector. Ranked #1122 out of 4700 analysts, they have issued 45 stock ratings with a success rate of 83.44% and an average return of 23.87%.

Gregory Renza has a well-established track record, with 45 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 83.44% and an average return of 23.87%, underscoring their expertise and ability to identify winning opportunities for investors.

#1122

Out of 4700

45

Total Ratings

+83.44%

Success Rate

+23.87%

Average Return

Recent Ratings Analysis

EXEL

Jun 25, 2026

Target

$54.00

Current

$52.87

Performance

—

Gregory Renza rated EXEL as Hold on Jun 25, 2026, setting a price target of 54. The Hold stance appears justified, as shares hovered around 52.87 with a % move.

NUVL

Jun 10, 2026

Target

$124.00

Current

$123.58

Performance

0.19%

On Jun 10, 2026, NUVL was given a Hold rating by Gregory Renza, with a target price of 124. Market indecision, reflected in sideways trading near 123.58, supported the cautious call.

NRIX

Jun 09, 2026

Target

$32.00

Current

$19.30

Performance

23.40%

NRIX received a Buy rating from Gregory Renza on Jun 09, 2026, aiming for 32. Momentum has favored the Buy call, with shares climbing from 19.3 to 19.3, rewarding those who trusted the recommendation.

ABVX

Jun 02, 2026

Target

$135.00

Current

$92.51

Performance

—

On Jun 02, 2026, Gregory Renza published a Buy outlook on ABVX, with a target of 135. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 92.51.

FULC

Jun 02, 2026

Target

$4.00

Current

$3.76

Performance

—

Gregory Renza on Jun 02, 2026 assigned FULC a Hold rating, with a price target of 4. The Hold stance reflected consolidation, as shares held near 3.76.

REGN

May 18, 2026

Target

$778.00

Current

$623.43

Performance

-0.99%

On May 18, 2026, Gregory Renza reaffirmed REGN with a Buy rating, targeting 778. Market indecision has kept the 778 target in a holding pattern.

RVMD

May 18, 2026

Target

$179.00

Current

$169.77

Performance

17.59%

RVMD was rated Buy by Gregory Renza on May 18, 2026, with a price objective of 179. A bullish response from the market helped close the gap of 9.23 to the target.

CGON

May 14, 2026

Target

$82.00

Current

$68.72

Performance

-1.18%

On May 14, 2026, Gregory Renza initiated coverage on CGON with a Buy rating and target of 82. Neutral price movement of -1.18% leaves room for interpretation.

GILD

May 08, 2026

Target

$157.00

Current

$125.16

Performance

-4.70%

Gregory Renza issued a Buy recommendation for GILD on May 08, 2026, price target set at 157. The target of 157 remains in play, though confirmation will depend on future moves.

ONC

May 07, 2026

Target

$413.00

Current

$277.12

Performance

-12.58%

On May 07, 2026, ONC was evaluated by Gregory Renza, who gave a Buy rating and target of 413. Investors saw limited payoff as shares fell short of the 413 target.

AMGN

May 01, 2026

Target

$327.00

Current

$351.43

Performance

—

Gregory Renza rated AMGN as Hold on May 01, 2026, setting a price target of 327. The Hold stance appears justified, as shares hovered around 351.43 with a % move.

AGIO

Apr 30, 2026

Target

$36.00

Current

$36.28

Performance

29.57%

On Apr 30, 2026, AGIO was given a Buy rating by Gregory Renza, with a target price of 36. The stock rallied 29.57% after the rating, narrowing the gap to the target of 36 and validating the bullish stance.

VRDN

Apr 21, 2026

Target

$33.00

Current

$17.32

Performance

21.29%

VRDN received a Buy rating from Gregory Renza on Apr 21, 2026, aiming for 33. Momentum has favored the Buy call, with shares climbing from 17.32 to 17.32, rewarding those who trusted the recommendation.

IDYA

Jan 06, 2026

Target

$60.00

Current

$36.28

Performance

-0.08%

On Jan 06, 2026, Gregory Renza published a Buy outlook on IDYA, with a target of 60. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 36.28.

NUVB

Nov 24, 2025

Target

$11.00

Current

$6.46

Performance

-12.82%

Gregory Renza on Nov 24, 2025 assigned NUVB a Buy rating, with a price target of 11. The call has struggled to gain traction, with shares losing 12.82%.

AAPG

Nov 24, 2025

Target

$51.00

Current

$17.08

Performance

-46.67%

On Nov 24, 2025, Gregory Renza reaffirmed AAPG with a Buy rating, targeting 51. Shares slid 46.67% despite the recommendation, highlighting downside risks.

BCYC

Nov 24, 2025

Target

$10.00

Current

$3.96

Performance

-41.25%

BCYC was rated Hold by Gregory Renza on Nov 24, 2025, with a price objective of 10. Investors who stayed cautious avoided some of the 41.25% decline.

MNKD

Nov 24, 2025

Target

$9.00

Current

$3.84

Performance

-25.15%

On Nov 24, 2025, Gregory Renza initiated coverage on MNKD with a Buy rating and target of 9. The Buy call has yet to be validated as shares remain 5.16 away from the target.

XNCR

Nov 24, 2025

Target

$29.00

Current

$14.45

Performance

-13.68%

Gregory Renza issued a Buy recommendation for XNCR on Nov 24, 2025, price target set at 29. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

CATX

Nov 24, 2025

Target

$12.00

Current

$3.00

Performance

38.25%

On Nov 24, 2025, CATX was evaluated by Gregory Renza, who gave a Buy rating and target of 12. This case illustrates how a timely bullish rating can translate into tangible gains of 38.25%.

CRMD

Mar 26, 2025

Target

$12.00

Current

$8.39

Performance

17.18%

Gregory Renza rated CRMD as Outperform on Mar 26, 2025, setting a price target of 12. The call has proven timely, with shares rising 17.18% toward the price target of 12.

VSTM

Mar 21, 2025

Target

$14.00

Current

$3.85

Performance

-42.11%

On Mar 21, 2025, VSTM was given a Outperform rating by Gregory Renza, with a target price of 14. Despite the Buy call, shares fell from 3.85 to 3.85, challenging the optimistic stance.

INO

Mar 19, 2025

Target

$5.00

Current

$1.10

Performance

-43.88%

INO received a Sector Perform rating from Gregory Renza on Mar 19, 2025, aiming for 5. The Hold stance proved prudent, with the market softening by 43.88%.

JAZZ

Feb 26, 2025

Target

$178.00

Current

$229.85

Performance

59.43%

On Feb 26, 2025, Gregory Renza published a Outperform outlook on JAZZ, with a target of 178. Shares gained 59.43%, underscoring the accuracy of the bullish outlook toward 178.

PCRX

Jan 14, 2025

Target

$18.00

Current

$23.96

Performance

16.59%

Gregory Renza on Jan 14, 2025 assigned PCRX a Sector Perform rating, with a price target of 18. Shares outperformed expectations, climbing 16.59% despite the neutral view.

JSPR

Jan 09, 2025

Target

$48.00

Current

$0.49

Performance

—

On Jan 09, 2025, Gregory Renza reaffirmed JSPR with a Outperform rating, targeting 48. Market indecision has kept the 48 target in a holding pattern.

CDTX

Dec 13, 2024

Target

$34.00

Current

$221.38

Performance

867.57%

CDTX was rated Outperform by Gregory Renza on Dec 13, 2024, with a price objective of 34. A bullish response from the market helped close the gap of -187.38 to the target.

SPRB

Dec 11, 2024

Target

$1.50

Current

$51.87

Performance

61.02%

On Dec 11, 2024, Gregory Renza initiated coverage on SPRB with a Sector Perform rating and target of 1.5. The Hold stance underestimated the stock’s strength as it gained 61.02%.

VRCA

Oct 04, 2024

Target

$11.00

Current

$5.85

Performance

346.56%

Gregory Renza issued a Outperform recommendation for VRCA on Oct 04, 2024, price target set at 11. Investors following the Buy call captured upside momentum, with shares now at 5.85.

VIRX

Aug 15, 2024

Target

$4.00

Current

$0.01

Performance

-97.19%

On Aug 15, 2024, VIRX was evaluated by Gregory Renza, who gave a Outperform rating and target of 4. Investors saw limited payoff as shares fell short of the 4 target.

ATYR

Aug 14, 2024

Target

$16.00

Current

$0.56

Performance

-69.65%

Gregory Renza rated ATYR as Outperform on Aug 14, 2024, setting a price target of 16. The stock has underperformed, dropping 69.65% despite the bullish target of 16.

MORF

Jul 26, 2024

Target

$57.00

Current

$56.99

Performance

0.78%

On Jul 26, 2024, MORF was given a Sector Perform rating by Gregory Renza, with a target price of 57. Market indecision, reflected in sideways trading near 56.99, supported the cautious call.

ACAD

Jun 25, 2024

Target

$29.00

Current

$23.36

Performance

49.74%

ACAD received a Outperform rating from Gregory Renza on Jun 25, 2024, aiming for 29. Momentum has favored the Buy call, with shares climbing from 23.36 to 23.36, rewarding those who trusted the recommendation.

Frequency Asked Questions

Who is Gregory Renza?

Gregory Renza is an analyst from Truist Securities specializing in the Healthcare sector.

What is Gregory Renza's success rate?

Gregory Renza currently has a success rate of +83.44%.

How many ratings has Gregory Renza issued?

Gregory Renza has issued 45 stock ratings so far.

What is the average return of Gregory Renza's calls?

Their stock ratings have generated an average return of +23.87%.

What is Gregory Renza's ranking?

Gregory Renza is ranked #1122 out of 4700 analysts.

What types of ratings does Gregory Renza give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Gregory Renza?

You can follow Gregory Renza by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Gregory Renza?

Their latest rating was a Hold on EXEL issued on 2026-06-25.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep